Cell Processing and Storage Core

细胞处理和存储核心

• 批准号: 8277827
• 负责人: Shelly Heimfeld
• 金额: $ 65.16万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8277827
• 关键词: Aliquot; Allogenic; Applications Grants; Blood donor; Bone Marrow; Cell Lineage; Cell physiology; Cells; Clinical; DNA; Data; Dendritic Cells; Development; Disease; Engineering; Engraftment; Flow Cytometry; Funding; Future; Generations; Grant; Hematopoietic; Homologous Transplantation; Immune; Individual; Lymphoid; Malignant - descriptor; Outcome; PRTN3 gene; Patient Care; Patients; Peripheral Blood Stem Cell; Preparation; Process; Public Health; Research; Research Personnel; Sampling; Services; Specimen; T-Lymphocyte; Technical Expertise; Techniques; Third-Party Payer; Transplant Recipients; Transplantation; WT1 gene; Work; adult leukemia; cGMP production; cost; disorder control; graft vs host disease; improved; instrumentation; novel; reconstitution; repository; response; success; tumor

Core E: Cell Processing and Storage will support this grant proposal by providing four specific functions. First, this core will provide critical instrumentation and technical expertise in cell procurement and processing of all clinical components necessary to support the treatment of patients with malignant diseases described in Projects 1-6. Direct funding is not requested for most of that activity, which is generally reimbursed by third party payers, but Core E will also procure and distribute research specimens and provide additional summary data to investigators. Second, the Core will characterize the bone marrow and PBSC components utilized in these allogeneic transplantation studies by quantitative flow cytometry for various T-cell and other lymphoid subsets. These data will be useful in determining which specific cell lineages may be correlated with clinical outcomes, which will in turn help to stimulate the development of novel graft engineering approaches and techniques that could improve future allogeneic transplantation studies. Third, Core E will operate a Repository of Research Specimens. This Repository will consist of two distinct types of components: (1) aliquots of patient and normal donor blood and/or bone marrow samples; (2) DNA preparations and established B-LCL lines obtained from allogeneic transplant patients and their corresponding normal donors. These samples will be critical in helping to define the mechanisms involved in engraftment, rejection, anti-tumor response and disease control, immune reconstitution, and the development of graft-versus-host disease. Material from this Repository will support studies outlined in Projects 1 , 2, 5, and 6. Fourth, Core E will be responsible for the development and clinical implementation of cell processing techniques necessary for the cGMP production of the WT1 and PR3 T-cells described in Project 5, and for the depletion of naive T-cells and subsequent generation of primed donor dendritic-cells described in Project 6. Integration of the clinical cell processing services of Core E with the projects contained within this grant application provides for better patient care, a higher degree of QA/QC, and significantly reduced efforts and costs. Relevance to public health: The support of Core E is critical to the success of the work proposed in the individual projects of this grant. This work promises to advance the field of allogeneic hematopoietic transplantation, making it safer, more effective, increasingly available and more appropriately applied. Such an advance could have obvious relevance to the thousands of patients who are transplanted each year or are potential candidates for transplantation.

核心E：单元格处理和存储将通过提供四个特定功能来支持此赠款建议。 首先，该核心将在细胞采购和处理中提供关键的工具和技术专长 在支持恶性疾病患者的治疗所必需的所有临床成分中 在项目1-6中。大多数活动都不要求直接资金，这通常由 第三方付款人，但核心E也将采购和分发研究标本，并提供其他 摘要数据向调查人员。其次，核心将表征骨髓和PBSC组件 在这些同种异体移植研究中通过定量流式细胞仪用于各种T细胞和其他 淋巴样子集。这些数据将在确定哪些特定细胞谱系可能相关的情况下很有用 有了临床结果，这将有助于刺激新型移植工程的发展 可以改善未来同种异体移植研究的方法和技术。第三，核心E将 操作研究标本的存储库。该存储库将包括两种不同类型的 组成部分：（1）患者和正常供体血和/或骨髓样品的等分试样； （2）DNA 从同种异体移植患者及其获得的制备和建立的B-LCL系 相应的正常供体。这些样本对于帮助定义涉及的机制至关重要 植入，排斥，抗肿瘤反应和疾病控制，免疫重构以及 移植物与宿主病的发展。该存储库的材料将支持概述的研究 项目1、2、5和6。第四，核心E将负责开发和临床实施 CGMP生产WT1和PR3 T细胞所述的细胞处理技术 项目5，以及幼稚的T细胞的耗竭以及随后产生的底漆供体树突状细胞 项目6中描述。将核心E的临床细胞处理服务集成到包含的项目 在此赠款中，应用程序提供了更好的患者护理，更高程度的QA/QC以及显着的 减少努力和成本。 与公共卫生的相关性：核心E的支持对于在 这笔赠款的个别项目。这项工作有望推进同种异体造血的领域 移植，使其更安全，更有效，越来越可用，并且更适当地应用。这样的 进步可能与每年被移植的数千名患者或 是移植的潜在候选者。